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Multiple myeloma is a haematological disorder of the bone marrow. It is preceded by the benign precursor 
monoclonal gammopathy of undetermined significance (MGUS). In multiple myeloma, a progression leading to 
expansion of malignant plasma cells occurs, causing skeletal lesions, anemia and renal insuffiency. Multiple 
myeloma is incurable, but the disease can be controlled with chemotherapy and other immunosuppressive drugs. 
It is known that both conditions have compromized immune responses, which lead to an increased risk of 
infections. However, there is no population-based data on the occurrence and type of infections in patients with 
plasma cell disorders compared to the normal population. Considering the cumulative immunodeficiency in 
patients with multiple myeloma, caused by multiple cytotoxic and immunomodulating therapies, there is a 
demand for less toxic treatments in the relapse setting, aiming to reduce morbidity and mortality in infections. 
Recent studies have suggested that immunomodulating treatment is beneficial even in smouldering  multiple 
myeloma. There is a lack of population-based incidence data in smouldering multiple myeloma patients with 
high risk of progressing to multiple myeloma, and there is a need of identifying patients with smouldering 
multiple myeloma that could benefit from up-front treatment.      
In paper I we investigated the treatment with intermediate-dose melphalan (Mel 100) and stem cell support in 
multiple myeloma patients relapsing after high dose melphalan and autologous transplantation (ASCT) in 66 
patients. With an overall response of 62%, limited toxicity and a progression-free survival of 8.5 months, we 
conclude that Mel 100 is a viable therapeutic option in relapsed patients and the best efficacy was seen in 
patients with long-lasting response after ASCT.     
In paper II and III we studied the risk of infections in MGUS and multiple myeloma patients compared to 
matched controls. Using population-based data from Sweden, in paper II we estimated the risk of infections 
among 5 326 MGUS patients compared to 20 161 matched controls. We found that patients with MGUS had a 2-
fold increased increased risk (hazard ratio (HR) 2.1; 95% confidence interval (CI) 2.0-2.3(p<0.05)) of 
developing any infection at 5-year follow up, and at 10-year follow up the risk was very similar (HR=2.2; 95% 
CI 2.0-2.3). Patients with M-protein concentration over 2.5 mg/dl had the highest risk of infections. In paper III 
we compared the risk of infections in 9 253 multiple myeloma patients to 34 931 matched controls. Overall, 
multiple myeloma patients had a 7-fold (HR =7.1; 95% CI 6.8-7.4) risk of developing any infection compared to 
matched controls. The increased risk of developing a bacterial infection was 7-fold (7.1; 6.8-7.4), and for viral 
infections it was 10-fold (10.0; 8.9-11.4). Multiple myeloma patients diagnosed in the more recent calendar 
periods had significantly higher risk of infections compared to patients diagnosed earlier (p<0.001). We could 
show, that in patients who died within the first year of diagnosis, 22 % of deaths were infection-related. Our 
findings provide novel insights into the mechanisms behind infections in patients with plasma cell disorders, and 
may have clinical implications and could give support to preventive interventions.   
In paper IV we estimated the risk of progression to symptomatic multiple myeloma in a cohort of smouldering 
multiple myeloma patients with high-risk features using population-based data from the Swedish Myeloma 
Registry. The 2-year risk of progressing was 56% and this cohort count for 29% of all smouldering myeloma 
patients and should be considered for clinical early treatment trials. 
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